Breast cancer diagnostic solutions Deliver diagnostic confidence

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Breast cancer diagnostic solutions Deliver diagnostic confidence"

Transcription

1 Breast cancer diagnostic solutions Deliver diagnostic confidence

2 2 Breast cancer diagnostic solutions Roche Tissue Diagnostics is committed to improving outcomes in breast cancer Breast cancer...the most common cancer type and cause of cancer-related deaths in women 1...annually claims more than 500,000 lives worldwide 1...in the US, 1 out of 8 women will develop invasive breast cancer during their lifespan 2 Breast cancer remains a significant scientific, clinical and societal challenge. Everyone s cancer diagnosis is as distinct as the person it affects. Breast cancer is heterogeneous in nature and has distinct biological, pathological and genetic diversity. Biomarkers can help identify patient subgroups most likely to benefit from a specific treatment. Diagnostic and prognostic descriptions of subtypes, guided by biomarker results, have become increasingly more sophisticated over the past decades.

3 Breast cancer diagnostic solutions 3 Precision medicine: The right test at the right time facilitates differential diagnosis Evidence supports that breast cancer tumors can be grouped into subtypes with distinct clinical profiles and treatment options. 3 Understanding the diversity in breast cancer allows for stratification of patient subgroups. Individual biomarkers (or panels of biomarkers) characterize subtypes, confirm origin of tissue, differentiate primary from metastatic tumor and provide prognostic and predictive information. 4 Biomarkers play an important role in the detection and management of patients 5 Biomarkers are the most precise way of identifying intrinsic subtypes 6 Failure to correctly stratify a patient can lead to unnecessary and costly exposure to therapeutics, prevent the delivery of the most beneficial treatment and may reduce the degree of positive outcomes 7,8,9 Three reasons to choose Roche Tissue Diagnostic s Solutions Our breast cancer diagnostics deliver on three key benefits that are valued by pathology professionals: 1. Clinical utility With proven accuracy 15,21 our breast cancer diagnostic assays help you identify patients other assays can miss 7,9,16,17 so you can deliver the right test, with clinical confidence in the shortest possible time. Our mission is to improve the lives of all patients afflicted with cancer. We are committed to empowering you in your quest to elevate the standard of care. 2. Analytical performance Specific and sensitive rabbit monoclonal antibodies, bestin-class probes, and powerful detection systems help you diagnose precisely and confidently. 3. Testing efficiency Our comprehensive breast cancer workflow solution delivers fully automated assays on market-leading platforms, with digital pathology and workflow solutions that free resources, reduce labor costs, and reduce time to results.

4 4 Breast cancer diagnostic solutions Biomarker status helps to identify patient groups most likely to respond to a specific treatment HER2 overexpression accounts for 15% to 20% of all breast cancers. Tumors that overexpress the HER2 gene are associated with more rapid growth compared to HER2 negative tumors. 6,10,12 Estrogen Receptor (ER) and Progesterone Receptor (PR) positive tumors account for approximately 74% of all breast cancer tumors. Dual positive hormone receptor tumors are usually slow growing and less aggressive. 5 Luminal A tumors have favorable short-term prognosis and show favorable response to hormonal therapy. 5 Luminal B tends to be more aggressive and higher grade than Luminal A. 5 In early breast cancer, moderate to strong PR expression is an aid to differentiate between Luminal A and B tumors. 12 Classifications of IHC subtypes: St. Gallen Consensus 12 Erb-B2 overexpression (non-luminal) Luminal A Luminal B (Her2 +) Luminal B (Her2 -) Basel like (Ductal, TN) HER2 + Overexpressed or amplified ER PR - + Any Negative or low - Ki-67 Low Any High Key + positive - negative This chart is not for diagnostic use. It represents staining patterns that are associated with breast cancers based on St. Gallen Expert Consensus, TN triple negative

5 Breast cancer diagnostic solutions 5 Pathology assessments play a critical role in breast cancer management Breast cancer management is complex and biomarkers play an integral role in determining the status of the tumor. IHC and ISH biomarkers help facilitate decision-making for subsequent therapeutic options. 3,6,10 The benefit of chemotherapy is dependant on multiple factors: Tumor size, lymph node involvement and the presence of biomarkers. 5 Multiple tests used to determine treatment 11 HER2 status Treatment decision Hormone receptor status HER2+ Hormone therapy * and targeted therapy ER+ and/or PR+ HER2- HER2- Hormone therapy * Breast cancer histology HER2+ Targeted therapy* ER- and/or PR- Non-targeted therapy* Source: Diagram is developed based on NCCN Guideline for Invasive Breast Cancer 11 * Targeted therapy can include chemotherapy with trastuzumab for HER2 positive patients, hormone therapy is for ER and/or PR positive patients, non-targeted therapy refers to chemotherapy for patients with triple negative status.

6 6 Breast cancer diagnostic solutions Provide confidence in your lab with Roche Tissue Diagnostics HER2 testing Breast carcinoma HER2 Dual ISH non-amplified, Magnification: 40X INFORM HER2 Dual ISH DNA Probe cocktail INFORM HER2 Dual ISH DNA Probe cocktail is designed to detect amplification of the HER2 gene and is indicated as an aid in the assessment of patients for whom Herceptin treatment is being considered. 13 ISH utilized as a reflex for IHC equivocal (2+) results Patient breast tissue sample Standardized and validated test platforms Adequate (formalin) fixation (6-72h) Results are easily scored using brightfield microscopy in-house with familiar technologies HER2 gene amplification assessment over the entire slide not just a pre-selected area facilitates scoring and identification of heterogeneity Simultaneous morphological assessment independent of H&E stain Archivable results allow for easy maintenance and simplifies consults in difficult cases Enhanced technical support tools including clear, consolidated guidance on best practices and streamlined training H&E stain Primary staining shows morphologic changes IHC Controls passed No significant staining in normal epithelium No faint or partial staining a Weak complete staining a Greater than 10% Intense complete staininga Greater than 10% ISH Report as HER2 positive oncologist for HER2-targeted therapies 2 2 a) Membrane staining

7 7 Breast cancer diagnostic solutions In a recent publication7 assessing the socioeconomic impact of inaccurate HER2 breast cancer testing, laboratory-developed in vitro diagnostic (IVD) were compared to U.S. Food and Drug Administration-approved IVD, found a cost benefit in using an approved IVD test. Breast carcinoma HER2 (4B5) positive, Score: 3+ Magnification: 40X HER2/neu (4B5)* Rabbit Monoclonal Primary Antibody The use of pre-dilutedpathway HER2 (4B5),14 in combination with the fully automated BenchMark IHC/ISH slide staining instrument, standardizes all IHC processes from baking through staining, and reduces the possibility of human error. It also minimizes inherent variability resulting from individual reagent dilution and other processes found in manual and semi-automated IHC methods. The PATHWAY HER2 (4B5) Primary Antibody empowers you to: Achieve consistently high proficiency assessment scores with HER2 (4B5) antibody, compared to other clones15 Employ the most widely adopted and reliable HER2-IHC primary antibody15 High concordance with HER2 FISH16,17 Proportion of sufficient stains (optimal or good) HER2 (4B5): Consistent high performance* competitor 1 concentrate competitor 1 ready-to-use competitor 2 ready-to-use HER2 4B5* (pre-dilute) Assessments *Data refers to PATHWAY and VENTANA products. Based on 5 years of data from a leading external quality assessment scheme. Retrieved from

8 8 Breast cancer diagnostic solutions Provide an aide in the management, prognosis and prediction of therapy outcomes of breast cancer Breast carcinoma ER (SP1) positive, Magnification: 40X Breast carcinoma PR (1E2) positive, Magnification: 40X CONFIRM anti-estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody and CONFIRM anti-progeserone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody ER is a powerful predictor of response to hormone therapy (such as Tamoxifen) and clinical outcome of breast cancer patients. PR status can add additional prognostic and predictive value to ER status by providing an independent and significant tool for predicting hormone therapy response and clinical outcome. 18 Indicated as an aid in patient management, prognosis, and the prediction of therapy outcomes in breast cancer 19,20 Rapid and consistent results delivered through fully automated platforms and digital pathology solutions ER (SP1) is a significant predictor of disease-specific survival 9,21 Achieve consistently high proficiency assessment scores with ER (SP1) antibody, compared the other clones 15 PR (1E2) antibody provides significant value as a prognostic factor and response prediction of hormone therapy, even in ER negative patients 18 ER (SP1): Consistent high performance* competitor 1 Proportion of sufficient stains (optimal or good) competitor 2 competitor 3 competitor 4 competitor 5 competitor 6 ER2 (SP1) (pre-dilute) Assessments *Based on 5 years of data from a leading external quality assessment scheme. Retrieved from

9 Breast cancer diagnostic solutions 9 Supporting breast cancer diagnostics Breast carcinoma Ki-67 (30-9) stained Magnification: Low Breast carcinoma E-cadherin (36) stained Magnification: 40X CONFIRM anti-ki-67 (30-9) Rabbit Monoclonal Primary Antibody CONFIRM Ki-67 (30-9) Antibody is directed against C-terminal portion of Ki-67 antigen. Staining for Ki-67 can be used to aid in assessing the proliferative activity of normal and neoplastic tissue. With intense nuclear staining and no adipose (K2) or cell membrane staining (MIB-1), CONFIRM Ki-67 (30-9) rabbit monoclonal antibody can help deliver a confident assessment of tumor aggressiveness. 22,23 Uncontrolled proliferation is a hallmark of malignancy. The 2013, St Gallen Expert Concensus 12 found that the degree of proliferative activity in breast cancer helped differentiate Luminal A from Luminal B tumors. VENTANA anti-e-cadherin (36) Mouse Monoclonal Primary Antibody Ventana E-cadherin (36) antibody is directed against the cytoplasmic domain of the human transmembrane protein E-cadherin expressed as a part of the cell-cell adhesion complex in epithelial tissues. 24 Reduction or loss of expression is associated with invasive carcinoma and possibly metastasis in a variety of carcinomas. This antibody may be used to aid in the differentiation of in-situ and/or invasive lobular carcinoma from in situ and/or invasive ductal carcinoma of the breast. CONFIRM p53 (DO-7) Primary Antibody CONFIRM p53 (DO-7) is used in conjunction with VENTANA Companion Algorithm p53 (DO-7) image analysis application using the VENTANA iscan Coreo Au scanner and VIRTUOSO software. 25 GATA3 (L50-823) Mouse Monoclonal Primary Antibody Use of this antibody is indicated as an aid in the identification of breast carcinomas within the context of an antibody panel, clinical history and a qualified pathologist. 26 GATA3 expression is primarily seen in breast carcinoma and urothelial carcinoma and only rarely found in tumors from other organs. 26 Mammaglobin (31A5) Rabbit Monoclonal Antibody Use of this antibody is indicated as an aid in the identification of metastatic breast carcinomas within the context of an antibody panel, clinical history and a qualified pathologist. 27 When combined with other breast-restricted markers such as GCDFP-15, an overall sensitivity for breast carcinoma of 84% has been achieved. 27

10 10 Breast cancer diagnostic solutions Digital pathology: Virtual consultation, image analysis and education Roche Digital Pathology is transforming the practice of pathology by developing innovative technologies that deliver medical value, inform decision making and improve cancer care. The integrated solution consists of high-quality scanners, image analysis software, image and workflow management software and education applications, all working together globally to optimize laboratories. Digital pathology enables more efficient and informed treatment decisions for patients enchanting care by eliminating the boundaries of time and distance. Your benefit Virtual consultation Maximize pathologist time Enable flexibility for tumor boards, case sharing and collaboration Enable fast turnaround time for expert opinions Provide access to sub-specialists Image analysis Build clinical confidence with US and CE-IVD validated Companion Algorithm image analysis software Facilitate consistent, objective interpretations for breast IHC verified by a pathologist for every patient Education Enrich and accelerate learning in a collaborative environment Allow students to review material anywhere, anytime, from the device of their choice Product features VENTANA Virtuoso image and workflow management software Anytime, anywhere access to slide images Optimize digital workflow and decision-making environment Web-based application to support remote consults and image analysis VENTANA Companion Algorithm image analysis software US and CE-IVD validated image analysis algorithms for the full breast panel: HER2, ER, PR, Ki-67 and p53 Semi-quantitative scores for markers requiring cell counts Fully validated as part of a systems approach includes reagents, staining platforms, scanners and software VENTANA iscan Coreo slide scanner Intended for low- to mid- volume scanning sites Brightfield scanning capability (160 slide capacity) at various magnifications 4x, 10x, 20x, 40x Live mode (remotely controlled microscope) VENTANA iscan HT slide scanner Intended for high-volume scanning sites Brightfield scanning capability (360 slide capacity) at various magnifications 20x, 40x Continuous random access and STAT processing with no workflow interruption VENTANA Vector education and collaboration software Support education and collaboration with digital images Standardize content and eliminate sharing resources (slides or microscopes) Allow students to review material anywhere, anytime, from the device of their choice (mobile-capable on ios and Android devices)

11 Breast cancer diagnostic solutions 11 World-class antibodies to stratify breast cancer Product Name Catalog no. Ordering code Tests CA-125 (OC125) Mouse Monoclonal Antibody Calponin-1 (EP798Y) Rabbit Monoclonal Antibody E-cadherin (36) Mouse Monoclonal Primary Antibody, VENTANA E-cadherin (EP700Y) Antibody Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody, CONFIRM Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody, CONFIRM FOXA1(2F83) Mouse Monoclonal Primary Antibody GATA3 (L50-823) Mouse Monoclonal Primary Antibody GCDFP-15 (EP1582Y) Rabbit Monoclonal Antibody GLIAL Fibrillary Acidic Protein (EP672Y) Rabbit Monoclonal Antibody Growth Hormone (polyclonal) Human Placental Lactogen (hpl) (polyclonal) HER2 Dual ISH DNA Probe Cocktail, INFORM HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody, PATHWAY Her-2/neu (4B5) Rabbit Monoclonal Primary Antibody, VENTANA Ki-67 (30-9) Rabbit Monoclonal Primary Antibody, CONFIRM Mammaglobin (31A5) Rabbit Monoclonal Antibody P53 (BP53-11) Primary Antibody P53 (DO-7) Primary Antibody, CONFIRM P57 (Kp10) Mouse Monocloncal Primary Antibody p63 (4A4) Mouse Monoclonal Primary Antibody, VENTANA P120 CATENIN (98) Mouse Monoclonal Primary Antibody, VENTANA PAX8 (MRQ-50) Mouse Monoclonal Primary Antibody PLAP (NB10) Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody PTEN (SP218) Rabbit Monoclonal Primary Antibody Topoisomerase IIα (JS5B4) Rabbit Monoclonal Primary Antibody Experience the power and confidence that comes from bringing VENTANA breast cancer diagnostics to your practice and patients today. For more information, contact your local Account Manager or visit us at

12 References 1. International Agency for Research on Cancer (IARC) and World Health Organization (WHO). GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in Accessed August 29, U.S. breast cancer statistics Accessed August 29, Parker JS, Mullins M, Cheang M. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8): Zaha, DC. Significance of immunohistochemistry. World J Clin Oncol. 2014;5(3): American Cancer Society: Breast cancer: Facts and figures Web site. acspc pdf Assessed September 19, Purrington KS, Visscher DW, Wang C. Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. Breast Cancer Res Treat [Epub ahead of print] doi: /s Vyberg M, Nielsen S, Røge R, et al. Immunohistochemical expression of HER2 in breast cancer: Socioeconomic impact of inaccurate tests. BMC Health Services Research. 2015;15: Luo D, Smith JA, Meadows NA. et al. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Frontiers in Genetics;6 Atricle357: Welsh AW, Harigopal M, Wimberly H, et al. Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol. 2013;2: Wolff AC, Hicks D, Hammond E. Recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31(31): NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 3, Accessed September 19, Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of Oncology. 2013;24: INFORM HER2 Dual ISH DNA Probe Cocktail Assay Package Insert. 15. NordiQC Assessments. Accessed September 19, Mayr D, et al. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (VENTANA) for VENTANA BenchMark automatic staining system with correlation to results of BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Archiv. 2009; 454(3): Brügmann A, Lelkaitis G, Nielsen S, et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol. 2011;19(3): Liu, S, Cchia SK, Mehl, E, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 2010;119: CONFIRM anti-estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody [package insert]. Tucson, AZ: VENTANA Medical. 20. CONFIRM anti-progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody [package insert]. Tucson, AZ: VENTANA Medical Systems, Inc.; Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, et al. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer. Mod Patholo 2013: 26): Leonardo E, Volante M, Barbareschi. et al. Cell membrane reactivity of MIB-1antibody to Ki-67 in human tumors: Fact or artifact? Appl Immunohistochem Mol Morphol. 2007;15(2): Miller R. Ki-67 clone K-2: A useful marker of fat cells and lipoblasts ProPath The Focus-Immunochistochemistry. Published February VENTANA anti-e-cadherin (36) Mouse Monoclonal Primary Antibody [package insert]. Tucson, AZ: VENTANA Medical Systems, Inc.; CONFIRM p53 (DO-7) Primary Antibody. [package insert]. Tucson, AZ: VENTANA Medical Systems, Inc.; GATA3 (L50-823) Mouse Monoclonal Primary Antibody. [package insert]. EN Rev. 0.1 v Mammaglobin (31A5) Rabbit Monoclonal Antibody. [package insert]. EN Rev VENTANA anti-her-2/neu (4B5) Rabbit Monoclonal Primary Antibody Package Insert. Ventana Medical Systems, Inc E. Innovation Park Drive Tucson, AZ USA Ventana Medical Systems, Inc. All trademarks mentioned enjoy legal protection. VENTANA, BENCHMARK, COMPANION ALGORITHM, CONFIRM, ISCAN COREO, VENTANA ISCAN, VENTANA VECTOR and VIRTUOSO are trademarks of Roche. All other trademarks are the property of their respective owners. 6073B 0217 RTDPC-ASFASA-0105

Digital Pathology and CAP Guidelines

Digital Pathology and CAP Guidelines Digital Pathology and CAP Guidelines Frequently asked questions The VENTANA family of digital pathology products empowers you with the convenience of a comprehensive image and workflow solution. When used

More information

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME Maria Lunardi MD Anatomic Pathology Fracastoro Hospital San Bonifacio, Verona -Italy HER2-neu

More information

Optimization of antibodies, selection, protocols and controls Breast tumours

Optimization of antibodies, selection, protocols and controls Breast tumours Optimization of antibodies, selection, protocols and controls Breast tumours Søren Nielsen Project coordinator & Scheme Manager NordiQC Aalborg University Hospital, Denmark Breast panel: GCDFP-15 Mammaglobin

More information

Assessment Run B HER2 IHC

Assessment Run B HER2 IHC Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.

More information

Molecular Probes Introducing 14 new probes

Molecular Probes Introducing 14 new probes Molecular Probes Introducing 14 new probes Gene and Chromosome Probes Dual Colour ISH INFORM HER2 Dual ISH DNA Probe Cocktail Assay Product Part Number INFORM HER2 Dual ISH DNA Probe Cocktail 800-4422

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Assessment Run C1 2017

Assessment Run C1 2017 Assessment Run C1 2017 PD-L1 The first assessment in this new NordiQC Companion module C1 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories to identify patients

More information

PD-L1 Analyte Control DR

PD-L1 Analyte Control DR Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1

More information

Assessment Run GATA3

Assessment Run GATA3 Assessment Run 44 2015 GATA3 Material The slide to be stained for GATA3 comprised: 1. Tonsil 2. Kidney, 3. Urothelial carcinoma, 4. Breast ductal carcinoma, 5. Colon adenocarcinoma All tissues were fixed

More information

Correlation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia

Correlation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67

More information

Determination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?

Determination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined? Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #449 (NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies National Quality Strategy Domain: Efficiency and Cost Reduction 2017 OPTIONS

More information

NIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1.

NIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1. NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 January ; 19(1): 144 147. doi:10.1158/1055-9965.epi-09-0807. Feasibility Study for Collection

More information

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,

More information

Image analysis in IHC overview, considerations and applications

Image analysis in IHC overview, considerations and applications Image analysis in IHC overview, considerations and applications Rasmus Røge, MD, Institute of Pathology, Aalborg University Hospital NordiQC workshop September 2016 Aalborg, Denmark Outline Theory Image

More information

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell

More information

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC VENTANA (SP142) Assay Guiding immunotherapy in NSCLC Hiker s path: VENTANA (SP142) Assay on non-small cell lung cancer tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess NSCLC patient benefit

More information

DOUBLE STAINS. Toll-Free: Direct:

DOUBLE STAINS. Toll-Free: Direct: DOUBLE STAINS CD61 + CD71 DAB Brown: CD61 Alk. Phos. Red: CD71 Bone Marrow DAB Brown: Megakaryocytes Alk. Phos. Red: Erythroid Precursors 400x CD61 (2f2) 0.1 ml concentrate............. 161M-14 0.5 ml

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade

HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,

More information

Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA 2

Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA 2 Hindawi Publishing Corporation Pathology Research International Volume 2012, Article ID 947041, 7 pages doi:10.1155/2012/947041 Clinical Study The Effect of Cold Ischemia Time and/or Formalin Fixation

More information

Carcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève

Carcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available

More information

T he HER2/neu type 1 tyrosine kinase growth factor

T he HER2/neu type 1 tyrosine kinase growth factor 710 ORIGINAL ARTICLE HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis

More information

Single and Multiplex Immunohistochemistry

Single and Multiplex Immunohistochemistry Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch

More information

Present Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy

Present Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy Present Role of Immunohistochemistry in the Classification of Molecular Subtypes Beppe Viale European Institute of Oncology University of Milan Milan-Italy We know it is many diseases Breast cancer is

More information

Data Supplement 1: 2013 Update Rationale and Background Information

Data Supplement 1: 2013 Update Rationale and Background Information Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology /College of American Pathologists Clinical Practice Guideline Update (edited

More information

Your Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:

Your Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help: Your Guide to the Breast Cancer Pathology Report Key Questions Here are important questions to be sure you understand, with your doctor s help: Your Guide to the Breast Cancer Pathology Report 1. Is this

More information

CME/SAM. Abstract. Anatomic Pathology / Image Analysis of HER2 Immunostaining

CME/SAM. Abstract. Anatomic Pathology / Image Analysis of HER2 Immunostaining Anatomic Pathology / Image Analysis of HER2 Immunostaining Image Analysis of HER2 Immunohistochemical Staining Reproducibility and Concordance With Fluorescence In Situ Hybridization of a Laboratory-Validated

More information

Is digital pathology ready for use in routine histopathology? Dr David Snead University Hospitals of Coventry and Warwickshire NHS Trust Coventry UK

Is digital pathology ready for use in routine histopathology? Dr David Snead University Hospitals of Coventry and Warwickshire NHS Trust Coventry UK Is digital pathology ready for use in routine histopathology? Dr David Snead University Hospitals of Coventry and Warwickshire NHS Trust Coventry UK Pathologists and microscopes. 1850 Rudolph Virchow (1821-1902),

More information

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment

More information

The Oncotype DX Assay A Genomic Approach to Breast Cancer

The Oncotype DX Assay A Genomic Approach to Breast Cancer The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast

More information

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer ARTICLE Ki67 Index, HER2 Status, and Prognosis of Patients With Breast Cancer Maggie C. U. Cheang, Stephen K. Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri Davies,

More information

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University

More information

SCIENCE CHINA Life Sciences

SCIENCE CHINA Life Sciences SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective

More information

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue. Innovation for your breast cancer diagnostics PGR G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C ERBB2

More information

Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients

Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients Breast Cancer (2013) 20:336 341 DOI 10.1007/s12282-012-0341-6 ORIGINAL ARTICLE Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients Rikiya Nakamura Naohito Yamamoto

More information

The Expression of Basal Cytokeratins in Breast Cancers

The Expression of Basal Cytokeratins in Breast Cancers Global Journal of Medical Research: C Microbiology and Pathology Volume 17 Issue 2 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online

More information

ONCOLOGY LETTERS 5: , 2013

ONCOLOGY LETTERS 5: , 2013 ONCOLOGY LETTERS 5: 559-563, 2013 The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel GIL BAR-SELA

More information

Mdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often

More information

ISPUB.COM. C Choccalingam, L Rao INTRODUCTION ESTROGEN AND PROGESTERONE RECEPTORS

ISPUB.COM. C Choccalingam, L Rao INTRODUCTION ESTROGEN AND PROGESTERONE RECEPTORS ISPUB.COM The Internet Journal of Pathology Volume 13 Number 1 Learning Experience In Immunohistochemical Reporting Of Breast Cancer At A Rural Tertiary Hospital In India: A Comparison In Initial And Reviewed

More information

Hormone receptor and Her2 neu (Her2) analysis

Hormone receptor and Her2 neu (Her2) analysis ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting

More information

Milestones in Her 2 Testing

Milestones in Her 2 Testing Human Epidermal Growth Factor Receptor 2 (HER2) Testing - Validation, Application and Correlation Her2 is encoded by the C-erbB2 gene and is one of four oncoproteins belonging to the Human Epidermal Growth

More information

Breast cancer classification: beyond the intrinsic molecular subtypes

Breast cancer classification: beyond the intrinsic molecular subtypes Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification

More information

Luminal A and B Where are we? (or lost in translation?)

Luminal A and B Where are we? (or lost in translation?) Luminal A and B Where are we? (or lost in translation?) Emiel J. Rutgers The Netherlands Cancer Institute Antoni Van Leeuwenhoek Hospital Amsterdam How to determine adjuvant or neoadjuvant treatment for

More information

Conflict of interest. Gynecologic Pathology. Gynecologic Pathology

Conflict of interest. Gynecologic Pathology. Gynecologic Pathology The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix, vagina and vulva Conflict of interest None (but the ovary is my favorite organ) Ålborg, June 10, 2015 Prof. Ben

More information

Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology

Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology Ugur Ozerdem, M.D. 1 Abstract Background: There is a paradigm shift in breast biopsy philosophy. In

More information

HPV/p16 Analyte Control

HPV/p16 Analyte Control HPV/p16 Analyte Control Utility review and ring study results Colin Tristram, Director 2017 HPV/p16 Analyte Control Collaboration: Dr Max Robinson at Newcastle University a leading pathologist in head

More information

METRIC Study Key Eligibility Criteria

METRIC Study Key Eligibility Criteria The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).

More information

HER2 status in breast cancer: experience of a Spanish National Reference Centre

HER2 status in breast cancer: experience of a Spanish National Reference Centre Clin Transl Oncol (2011) 13:000-000 DOI RESEARCH ARTICLES HER2 status in breast cancer: experience of a Spanish National Reference Centre Marta Cuadros Carlos Cano Francisco Javier López Paloma Talavera

More information

Tumour markers in breast carcinoma correlate with grade rather than with invasiveness

Tumour markers in breast carcinoma correlate with grade rather than with invasiveness doi: 10.1054/ bjoc.2001.1995, available online at http://www.idealibrary.com on http://www.bjcancer.com Tumour markers in breast carcinoma correlate with grade rather than with invasiveness F Wärnberg

More information

J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

More information

Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies

Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Victoria Sujoy, MD, Mehrdad Nadji, MD, and Azorides R. Morales, MD From

More information

UCL-Advanced Diagnostics. 2015/16 Service Update

UCL-Advanced Diagnostics. 2015/16 Service Update UCL-Advanced Diagnostics 2015/16 Service Update About UCL-Advanced Diagnostics UCL Advanced Diagnostics (UCL-AD) is the immunohistochemistry, in situ and molecular diagnostics service arm of the UCL-Cancer

More information

UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF GENERAL MEDICINE DOCTOR S DEGREE THESIS ABSTRACT

UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF GENERAL MEDICINE DOCTOR S DEGREE THESIS ABSTRACT UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF GENERAL MEDICINE DOCTOR S DEGREE THESIS ABSTRACT CLINICAL, HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY IN A GROUP OF PATIENTS WITH BREAST CANCERS

More information

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,

More information

CME/SAM. Ellen G. East, MD, 1 Judy C. Pang, MD, 1 Kelley M. Kidwell, PhD, 2 and Julie M. Jorns, MD 1 ABSTRACT

CME/SAM. Ellen G. East, MD, 1 Judy C. Pang, MD, 1 Kelley M. Kidwell, PhD, 2 and Julie M. Jorns, MD 1 ABSTRACT AJCP / Original Article Utility of Estrogen Receptor, Progesterone Receptor, and HER-/neu Analysis of Multiple Foci in Multifocal Ipsilateral Invasive Breast Carcinoma Ellen G. East, MD, Judy C. Pang,

More information

Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry

Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Nat Met, April 2014 Nat Med, April 2014 Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Journal Club Timo Böge Overview Introduction Conventional Immunohistochemistry

More information

Measure Definition Benchmark Endorsed By. Measure Definition Benchmark Endorsed By

Measure Definition Benchmark Endorsed By. Measure Definition Benchmark Endorsed By Process Risk Assessment Tumor Site: Breast Process Presence or Risk absence Assessment of cancer in first-degree blood relatives documented in patients with invasive breast Presence cancer or absence of

More information

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have

More information

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar

More information

Immunohistochemical principles The technical test approach. Pre-analytical parametres

Immunohistochemical principles The technical test approach. Pre-analytical parametres Immunohistochemical principles The technical test approach Pre-analytical parametres Søren Nielsen Global Pathology Manager Agilent Technologies (Former Scheme Manager, NordiQC) 2 IHC project coordinator

More information

microrna Presented for: Presented by: Date:

microrna Presented for: Presented by: Date: microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions

More information

P53 IS UNSTABLE DURING METASTATIC DEVELOPMENT OF THE HUMAN BREAST CANCER: A COMPARISON BETWEEN THE PRIMARY TUMOR AND LYMPH NODE METASTASIS

P53 IS UNSTABLE DURING METASTATIC DEVELOPMENT OF THE HUMAN BREAST CANCER: A COMPARISON BETWEEN THE PRIMARY TUMOR AND LYMPH NODE METASTASIS ORIGINAL ARTICLE P53 IS UNSTABLE DURING METASTATIC DEVELOPMENT OF THE HUMAN BREAST CANCER: A COMPARISON BETWEEN THE PRIMARY TUMOR AND LYMPH NODE METASTASIS ABSTRACT Veaceslav Fulga¹ 1 Department of Histology,

More information

Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY

Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY SCIENTIFIC COORDINATOR: PROF. DR. MIHAI B. BRĂILA, Ph.D. Ph.D. Graduand:

More information

ORIGINAL ARTICLE The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting

ORIGINAL ARTICLE The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting Malaysian J Pathol 2017; 39(2) : 141 148 ORIGINAL ARTICLE The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting Harshini PEIRIS PhD, Lakmini MUDDUWA MBBS, MD*, Neil THALAGALA

More information

Use of tissue micro array (TMA) in routine clinical analysis

Use of tissue micro array (TMA) in routine clinical analysis 2nd European Workshop on Tissue Imaging and Analysis June 25-26, 2010 Use of tissue micro array (TMA) in routine clinical analysis Tim Svenstrup Poulsen Molecular unit Dept. pathology Herlev Hospital Denmark

More information

Received 04 November 2008; Accepted in revision 09 January 2009; Available online 20 January 2009

Received 04 November 2008; Accepted in revision 09 January 2009; Available online 20 January 2009 Int J Clin Exp Pathol (2009) 2, 476-480 www.ijcep.com/ijcep811001 Original Article Immunohistochemical Detection of Estrogen and Progesterone Receptor and HER2 Expression in Breast Carcinomas: Comparison

More information

Title: Peritumoral Vascular Invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis

Title: Peritumoral Vascular Invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis Author's response to reviews Title: Peritumoral Vascular Invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis Authors: Andrea Malfettone

More information

Lung Anaplastic Lymphoma Kinase (lu-alk)

Lung Anaplastic Lymphoma Kinase (lu-alk) Assessment Run 5 207 Lung Anaplastic Lymphoma Kinase (lu-alk) Material The slide to be stained for lu-alk comprised:. Appendix, 2. Tonsil, 3. Merkel cell carcinoma, 4. Anaplastic large cell lymphoma with

More information

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis 658 & 2013 USCAP, Inc All rights reserved 0893-3952/13 $32.00 OPEN Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis Molly E Klein

More information

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin

More information

Gene Expression Profiling for Managing Breast Cancer Treatment. Policy Specific Section: Medical Necessity and Investigational / Experimental

Gene Expression Profiling for Managing Breast Cancer Treatment. Policy Specific Section: Medical Necessity and Investigational / Experimental Medical Policy Gene Expression Profiling for Managing Breast Cancer Treatment Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Pertuzumab for Treatment of Malignancies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pertuzumab_for_treatment_of_malignancies 2/2013 4/2017 4/2018 6/2017

More information

CME/SAM ABSTRACT. AJCP / Original Article

CME/SAM ABSTRACT. AJCP / Original Article Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2- Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab Hee Jin Lee, MD, PhD, 1 Joo Young

More information

Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer

Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer DOI:10.22034/APJCP.2017.18.4.1151 Trastuzumab RESEARCH ARTICLE Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast

More information

Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer

Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer MOLECULAR AND CLINICAL ONCOLOGY 2: 751-755 Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer RYOSUKE SHIBATA 1,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Urinary Tumor Markers for Bladder Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: urinary_tumor_markers_for_bladder_cancer 5/2011 11/2017 11/2018

More information

CME. CK5 Is More Sensitive Than CK5/6 in Identifying the Basal-like Phenotype of Breast Carcinoma

CME. CK5 Is More Sensitive Than CK5/6 in Identifying the Basal-like Phenotype of Breast Carcinoma Anatomic Pathology / CK5 vs CK5/6 in Breast Carcinoma CK5 Is More Sensitive Than CK5/6 in Identifying the Basal-like Phenotype of Breast Carcinoma Rohit Bhargava, MD, 1 Sushil Beriwal, MD, 2 Kim McManus,

More information

Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie

Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et

More information

Transform genomic data into real-life results

Transform genomic data into real-life results CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for

More information

Immunohistochemical studies (ER & Ki-67) in Proliferative breast lesions adjacent to malignancy

Immunohistochemical studies (ER & Ki-67) in Proliferative breast lesions adjacent to malignancy IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 13, Issue 3 Ver. IV. (Mar. 2014), PP 84-89 Immunohistochemical studies (ER & Ki-67) in Proliferative

More information

Setting The setting was secondary care. The economic study was conducted in the USA.

Setting The setting was secondary care. The economic study was conducted in the USA. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis Elkin E B, Weinstein K C, Winer E P, Kuntz K M, Schnitt S J, Weeks J C Record Status This is a critical

More information

One Breast Cancer Annual Report

One Breast Cancer Annual Report One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the

More information

Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review

Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review Sandra Lee MD, FRCPC 1 *, Vikrant V. Sahasrabuddhe, MBBS, DrPH 2 *, Diana

More information

Tykerb. Tykerb (lapatinib) Description

Tykerb. Tykerb (lapatinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.23 Subject: Tykerb Page: 1 of 5 Last Review Date: December 8, 2017 Tykerb Description Tykerb (lapatinib)

More information

Macro Trends in Health Care A Payer Perspective on Health Care Innovations Health IT, Genomics

Macro Trends in Health Care A Payer Perspective on Health Care Innovations Health IT, Genomics Macro Trends in Health Care A Payer Perspective on Health Care Innovations Health IT, Genomics Health Care Reform and Health IT: Making Health Care Value Real Charles Kennedy, M.D. VP Health Information

More information

Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast

Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast 10.14456/apjcp.2016.191/APJCP.2016.17.8.3911 Survival of Triple Negative and Triple Positive Breast Cancers RESEARCH ARTICLE Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison

More information

NEUROENDOCRINE DIFFERENTIATED BREAST CARCINOMA

NEUROENDOCRINE DIFFERENTIATED BREAST CARCINOMA + NEUROENDOCRINE DIFFERENTIATED BREAST CARCINOMA + INTRODUCTION + NEUROENDOCRINE FEATURES IN BREAST CARCINOMA Incidence of 2-5% Seen in various histopathological types of breast carcinoma Seen in both

More information

Differential diagnosis of HCC

Differential diagnosis of HCC Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis

More information

Studying the Correlation between Androgen Receptor (AR) Expression and Prognostic Factors in Invasive Breast Carcinoma

Studying the Correlation between Androgen Receptor (AR) Expression and Prognostic Factors in Invasive Breast Carcinoma Studying the Correlation between Androgen Receptor (AR) Expression and Prognostic Factors in Invasive Breast Carcinoma Sara Safi (1) Hasan Ehteram (1) Alireza Moraveji (2) Tahere Khamechian (1) Soheila

More information

Proceedings of the 36th World Small Animal Veterinary Congress WSAVA

Proceedings of the 36th World Small Animal Veterinary Congress WSAVA www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)

More information

Next generation image analysis for immunohistochemistry quantitation

Next generation image analysis for immunohistochemistry quantitation Next generation image analysis for immunohistochemistry quantitation Ben Vainer Department of Pathology, Rigshospitalet University of Copenhagen Medical Center Men are only so good as their technical developments

More information

Case Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland

Case Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland Pathology International 2008; 58: 322 326 doi:10.1111/j.1440-1827.2008.02231.x Case Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland Hidetaka Yamamoto, 1 Hideoki Uryu,

More information

Updates in Molecular Classification of Breast Cancer. Emmanuel Agosto-Arroyo, MD Assistant Member Department of Anatomic Pathology

Updates in Molecular Classification of Breast Cancer. Emmanuel Agosto-Arroyo, MD Assistant Member Department of Anatomic Pathology Updates in Molecular Classification of Breast Cancer Emmanuel Agosto-Arroyo, MD Assistant Member Department of Anatomic Pathology 3/3/2018 Disclosure There are no conflicts of interest. Objectives Describe

More information

Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón

Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense Madrid The new technologies

More information

Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts

Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Ovarian cancer is diagnosed annually in more than 200,000 women worldwide, with

More information